{"brief_title": "A Study of Isoprinosine in Patients With Severe AIDS", "brief_summary": "To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to: Laboratory (immunologic defects): - Comparison of total helper and suppressor T-cell numbers among the groups. - Comparison of changes in natural killer cell activity. - Comparison of other laboratory findings among the groups. Clinical changes: - Comparison of the frequency of opportunistic infections among the groups. - Comparison of the frequency of the development of AIDS-related malignancies. - Comparison of other clinical manifestations relative to severity and time of onset.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Inosine pranobex"], "criteria": "Exclusion Criteria Co-existing Condition: Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer are excluded. Concurrent Medication: Excluded: - Steroids. - Cytotoxic immunosuppressive agents. - Radiotherapy. The following are excluded: - Critically ill patients. - Patients receiving steroids, cytotoxic immunosuppressive agents, radiotherapy. - Patients who have received any other immunotherapy. - Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer. Prior Medication: Excluded: - Any other immunotherapy. Patients with severe AIDS and specified laboratory immunologic defects.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Biological Availability", "mesh_term": ["HIV Infections", "Immunologic Deficiency Syndromes", "Acquired Immunodeficiency Syndrome", "Inosine Pranobex"], "id": "NCT00002295"}